Key Highlights
- Total revenues were USD 25.32 million against an estimate of USD 25.57 million and USD 31.11 million a year earlier.
- Loss per share was USD 1.08 against an estimate of USD 0.30, compared with USD 0.29 last year.
- A USD 31.27 million Debt derivative Liability charge followed the signing of a Merger agreement on September 27.
- Cash was USD 23.0 million, with USD 15.0 million available on the revolver and USD 196.1 million term Loan borrowings.
Lifecore Biomedical, Inc. (NASDAQ:LFCR) is a fully integrated contract development and Manufacturing organization that fills complex sterile injectables and makes pharmaceutical-grade hyaluronic acid. Management described operational steps since May 2024, including a five-head aseptic isolator filler installed in September 2024 and a new enterprise resource planning system implemented in January 2026. On September 27, 2026, the company agreed to be acquired by affiliates of Webster Equity Partners, and the quarter includes a debt derivative charge linked to that agreement.
Operations, Customers and the Merger Agreement
The Business reports one segment with two activities. CDMO Revenue was USD 17.78 million against USD 21.75 million a year earlier, and hyaluronic acid manufacturing revenue was USD 7.55 million against USD 9.36 million. Within CDMO, the company cited USD 3.7 million of lower sales Volume and USD 2.3 million of lower pricing, mainly a price concession to a customer in exchange for a multi-year extension of its commercial agreement, partly offset by USD 1.7 million of higher development revenue from new programs. It linked lower hyaluronic acid revenue to timing at its largest customer.
Under the merger agreement, each common share converts into USD 6.28 in cash plus one contingent value right. Management named the end of the fourth quarter of 2026 as the closing point, subject to stockholder and regulatory approvals.
Financial Results
Total revenues were USD 25.32 million, including USD 11.74 million from a related party. Gross Profit was USD 6.83 million against USD 7.79 million, and gross profit percentage was 27.0% against 25.0%. Research and Development expenses were USD 1.42 million and selling, general and administrative expenses were USD 6.30 million. Operating loss was USD 0.89 million against USD 3.07 million.
Interest expense to a related party was USD 7.68 million, and the change in Fair Value of the debt derivative liability was a USD 31.27 million expense, against USD 0.38 million a year earlier. The company said the signing of the agreement raised the assumed probability and accelerated the assumed timing of a change in control, producing a derivative valuation of USD 62.2 million. Net loss was USD 40.08 million and loss available to common stockholders was USD 41.03 million, or USD 1.08 per share. For nine months, revenue was USD 82.68 million and the loss per share was USD 1.70.
Debt, Preferred Stock and Liquidity
Cash was USD 23.0 million, and USD 15.0 million was available under the USD 40.0 million revolving Credit facility, with nothing drawn. About USD 201.3 million of total indebtedness is owed to Alcon, including USD 196.1 million under the term loan, which carries a fixed 10% rate with 3% paid in cash since May 22, 2026, an effective rate of 20.9% and a May 22, 2029 maturity.
All 50,187 Series A Preferred Shares received Redemption notices, with a redemption date of December 28, 2026 under the terms. The aggregate Liquidation preference was USD 51.1 million. Management stated that internally generated cash is not projected to be sufficient to fund all or any significant redemptions, that the merger, if closed, would satisfy the obligation, and that the merger agreement prohibits cash redemptions.
Next Reporting Checkpoints
Revenue of USD 25.32 million sits alongside a loss of USD 1.08 per share, cash of USD 23.0 million and term loan borrowings of USD 196.1 million. The fourth quarter of 2026 is the period named for closing, and December 28, 2026 is the stated Series A redemption date.
The company also stated that its disclosure controls were not effective as of September 30, 2026 because a previously reported internal control issue was not yet fully remediated.


_11_20_2026_14_55_23_118425.jpg)



Please wait processing your request...